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Edited by Laszlo Nagy and Peter TontonozAbstract PPARd is the only member in the PPAR subfamily of
nuclear receptors that is not a target of current drugs. Animal
studies demonstrate PPARd activation exerts many favorable
eﬀects, including reducing weight gain, increasing skeletal mus-
cle metabolic rate and endurance, improving insulin sensitivity
and cardiovascular function and suppressing atherogenic inﬂam-
mation. These activities stem largely from the ability of PPARd
to control energy balance, reduce fat burden and protect against
lipotoxicity caused by ectopic lipid deposition. Therefore,
PPARd represents a novel therapeutic target and the develop-
ment of PPARd gonists/modulators may be useful for treating
the whole spectrum of metabolic syndrome.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Metabolic disease1. PPARd, a lipid sensing nuclear receptor
PPARd (also called PPARb), together with the other two
siblings, PPARa and PPARc, constitute the PPAR subfamily
of the nuclear receptor superfamily [1–3]. These receptors con-
trol transcription through binding to speciﬁc DNA elements,
consisting of two repeats of the core sequence AGGTCA sep-
arated by one nucleotide (DR-1), in the target gene promoters
[4]. They have been shown to be activated by dietary fatty
acids (FAs), particularly polyunsaturated FAs, and regulate
various aspects of metabolic processes. However, it is the iden-
tiﬁcation of the lipid-lowering ﬁbrates and insulin sensitizer
thiazolidinediones as ligands for PPARa and PPARc, respec-
tively, that sparks the extensive research in PPAR biologyAbbreviations: PPAR, peroxisome proliferator-activated receptor; FA,
fatty acid; ADRP, adipose diﬀerentiation-related protein; AOX, acyl-
CoA oxidase; CPT1, carnitine palmitoyltransferase 1; LCAD, long
chain acyl-CoA dehydrogenase; PGC-1b, peroxisome proliferators-
activated receptor c co-activator 1b; GLUT4, glucose transport 4;
FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; NASH, non-
alcoholic steaohepatitis; IBD, Inﬂammatory bowel disease; COX II,
cytochrome oxidase II; PDK4, pyruvate dehydrogenase kinase 4;
PDK1, 3-phosphoinositide-dependent 3-kinase; ILK, integrin-linked
kinase; ATGL, adipose triglyceride lipase; L-FABP, liver fatty acid
binding protein; Ihh, Indian hedgehog
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doi:10.1016/j.febslet.2007.11.040[5,6]. PPARd is the only subtype that is not a target of current
drugs. It is expressed in most metabolically active tissues. Early
work has identiﬁed adipose diﬀerentiation-related protein
(ADRP), a lipid droplet coating protein, as a PPARd target
gene and demonstrated that the ability of dietary fatty acids
carried by very low-density lipoprotein to regulate ADRP
expression is dependent on PPARd, implicating that this recep-
tor acts as a lipid sensor and is a potential therapeutic target to
treat metabolic diseases [7]. Subsequent studies have revealed
that PPARd controls an array of metabolic genes involved in
glucose homeostasis and fatty acid synthesis/storage, mobiliza-
tion and catabolism in a tissue-speciﬁc manner (Table 1). Sev-
eral synthetic ligands, namely GW501516, GW7042 and
L165041, have also been developed, each exhibiting diﬀerent
eﬃcacies in ameliorating symptoms of metabolic disorders
[8–11]. This review will discuss the biological activity of
PPARd in energy balance and how this activity modulates cel-
lular function as well as systemic metabolic homeostasis
(Fig. 1). Potential therapeutic implications of PPARd ago-
nists in treating metabolic diseases demonstrated in animal
models will be described. The eﬀects of GW501516 will be
the main focus of the discussion, as this compound is best
characterized.2. PPARd and metabolic control
2.1. Lipid storage and mobilization in placenta
Attempts to delineate PPARd function through the genera-
tion of knockout mice had generated limited information.
Two targeting lines were created, one had the deletion in the
DNA binding domain (DBD) and another in the C-terminus
of ligand binding domain, both of which resulted in embryonic
lethality [12,13]. A small number of PPARd/ pups that sur-
vived to term exhibited growth retardation and reduced
abdominal fat mass. Genotyping of embryos at diﬀerent gesta-
tion stages revealed that PPARd/ embryos died at around
day 10.5 due to placental defects, in which the connection be-
tween placentas and the material deciduas was abnormally
loose [12]. This phenotype was reproduced in the third knock-
out lines, also created by deletion in the DBD [14]. A close
examination of the defect uncovered that PPARd is required
for the diﬀerentiation of functional trophoblast giant cells,
which play an important role in processes such as material
deciduas remodeling and secretion of placental hormones.
PPARd does so by activation of the phosphatidylinositol 3-
kinase (PI3K)/Akt1 signaling pathway. Similar regulation ofblished by Elsevier B.V. All rights reserved.
Table 1
PPARd in cellular function and metabolism
Target cell/tissue Function Downstream signaling
Placenta giant cells Diﬀerentiation Akt1, PDK1, ILK, ADRP, etc. [14]
Keratinocytes Survival Akt1, PDK1, ILK [15]
Intestinal Paneth cells Diﬀerentiation L-FABP, Ihh [36]
Adipocytes Fatty acid catabolism, thermogenesis CPT1, AOX, LCAD, UCP1/3, etc. [17]
Skeletal muscle, cardiac muscle Fatty acid oxidation, oxidative metabolism CPT1, LCAD, UCP2/3, PDK4, COX II/IV,
PGC-1a etc. [18,19,22]
Macrophages Fatty acid metabolism, inﬂammation ADRP, CPT1, UCP2, ATGL, MCP-1/3, IL-1b, etc. [26,31]
Hepatocytes Lipogenesis, glucose metabolism Pentose phosphate pathway FAS, ACC2, etc. [25]
Fig. 1. Transcriptional regulation of metabolic homeostasis by PPARd. PPARd/RXR heterodimers bind to the DR-1 type response elements with a
core sequence AGGTCA on target gene promoters and turn on transcription upon ligand activation. Dietary fatty acids (FAs) carried by very low-
density lipoprotein (VLDL) have been shown to activate PPARd. PPARd controls many metabolic programs in glucose and fatty acid homeostasis
through direct transcriptional regulation, while its activity in suppressing inﬂammatory response is believed to be indirect. Pharmacological
activation of PPARd exerts many therapeutic eﬀects, including reducing hepatic glucose production, increasing fatty acid catabolism in adipocyte
and muscle and lowering the inﬂammatory status. In animal models, these eﬀects lead to attenuation of metabolic syndrome, such as obesity,
dyslipidemia and insulin resistance.
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and intestinal epithelial cells (see below) [15,16]. As the PI3K/
Akt signaling is critical in many cellular metabolic processes,
this ﬁnding is in line with the role of PPARd as a metabolic
sensor controlling vital cell functions. Interestingly, the expres-
sion of ADRP in placenta appears to be tightly associated with
giant cell diﬀerentiation and is regulated through both direct
transcriptional control and PI3k/Akt1 activation mediated by
PPARd. Although the function of ADRP in lipid metabolism
is not completely understood, it is proposed to be involved in
storing and perhaps compartmentalizing fatty acids to be used
for normal fetal development [14].
2.2. Adipocyte energy homeostasis
As mentioned earlier, the surviving PPARd/ mice had
reduced fat mass. Given that PPARc regulates the adipocyte
diﬀerentiation program, a role of PPARd in adipogenesis
was suspected. However, adipocyte-speciﬁc PPARd/ mice
showed no diﬀerence in sizes of both epidydimal white andinterscapular brown fat pads, suggesting that PPARd is not re-
quired for adipocyte diﬀerentiation [12]. The function of
PPARd in adipose tissue was realized later in transgenic mice
expressing an active form of PPARd (VP16 activation domain
fused to the N-terminus of PPARd, VP16-PPARd) driven by
the ap2 promoter [17]. This manipulation bypassed the use
of ligand and achieved constitutive PPARd activation in adi-
pocytes, resulting in mice that were lean and had a reduction
in body fat composition. Remarkably, these animals were pro-
tected from obesity induced by high fat diets or by deletion of
the leptin receptor gene. Gene expression analyses demon-
strated that in brown fat, PPARd activation induced genes in
fatty acid oxidation, including carnitine palmitoyltransferase
1 (CPT1), acyl-CoA oxidase (AOX) and long chain acyl-
CoA dehydrogenase (LCAD), and in thermogenesis/energy
dissipation, including uncoupling protein 1 (UCP1) and
UCP3. The expression change in white fat was less evident.
However, UCP-1, which was not present in white adipocyte
of wild type mice, was drastically up-regulated in transgenic
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brown fat-like phenotype in white adipose tissue (WAT). In-
deed, the cell sizes of WAT were signiﬁcantly decreased in
transgenic mice. Consistent with the observed gene regulation
in vivo, PPARd activation in cultured 3T3-L1 adipocytes or
C2C12 myotubes by ligand treatment also increased the
b-oxidation rate. Collectively, these data suggest that PPARd
increases fat combustion and this metabolic control may pro-
vide a means to regulate adiposity.2.3. Oxidative metabolism and muscle function
In skeletal muscle, PPARd is expressed at a higher level in so-
leus muscle, which consists of the fatigue resistant, type I ﬁbers
that are rich in mitochondria and use oxidative metabolism for
energy production. Conversely, PPARd is detected at a lower
level in gastrocnemius muscle, which contains a mixture of
the oxidative type I as well as glycolytic type II ﬁbers [18].
The increased fatty acid catabolism by PPARd in myotubes
indicates that this receptor may be a critical metabolic regulator
in muscle. To test this hypothesis, a similar transgenic approach
was conducted in mice to induce PPARd activation in muscle.
Remarkably, over-expression of either wild type PPARd or
VP16-PPARd in muscle resulted in ﬁber type switching, with
a 2-fold increase in type I ﬁbers in gastrocnemius muscle
[18,19]. This was accompanied by induction of mitochondria
numbers and genes of oxidative metabolism, fatty acid catabo-
lism and type I ﬁber markers. This phenotype resembles that of
muscle-speciﬁc over-expression of peroxisome proliferators-
activated receptor c co-activator 1a (PGC-1a), indicating a
functional interaction between PPARd and PGC-1a in muscle
[20]. As a consequence of enrichment in type I muscle ﬁbers
and enhanced oxidative capacity, these transgenic mice were
lean and had an improved metabolic status and increased run-
ning endurance tested in oxygen-infused treadmills. The role of
PPARd in skeletal muscle function was further validated in
muscle-speciﬁc PPARd/ mice, which exhibited reciprocal
phenotypes, including reduction in type I muscle ﬁbers,
depressed expression of genes in fatty acid uptake, catabolism,
energy uncoupling and mitochondrial electron transport chain,
increased weight gain and a mild defect in glucose metabolism
when challenged with a high fat diet [21]. Interestingly, the
expression of PGC-1a in muscle appeared to be under the con-
trol of PPARd, supporting the proposal that PGC-1a serves as
a co-activator of PPARd to control mitochondria biogenesis
and muscle ﬁber type plasticity [17,18,21].
Cardiomyocytes is another muscle type that utilizes fatty
acid as a main energy source. An intact fatty acid catabolic
capacity is therefore critical to maintain normal heart function.
Knowing its function in skeletal muscle, it is not surprising
that PPARd also serves as a key regulator of fatty acid catab-
olism in the heart. Cardiomyocyte-restricted PPARd/
resulted in decreased expression of CPT1, LCAD, AOX and
UCP3 and a reduced b-oxidation rate, leading to lipid accumu-
lation in the heart [22]. Assessment of cardiac performance
demonstrated that rates of cardiac contractility and relaxation
were reduced in cardiomyocyte PPARd/ mice. These mice
eventually developed cardiac hypertrophy and cardiomyopa-
thy and died between 4 and 10 months of age. This study dem-
onstrates that in the heart, PPARd regulates oxidative
metabolism not only for energy production but also for protec-
tion against lipotoxicity.3. PPARd and metabolic diseases
3.1. Obesity and dyslipidemia
The incidence of obesity has increased considerably, partly
caused by energy surplus and sedentary life styles. Accompa-
nied with it are metabolic abnormalities, including high blood
pressure, inﬂammation, insulin resistance, dyslipidemia (high
levels of triglyceride (TG) and low-density lipoprotein choles-
terol (LDL-c) and low levels of high-density lipoprotein cho-
lesterol (HDL-c), atherosclerosis and cancer [23]. Given that
forced PPARd activation in transgenic models protects against
obesity and induces an exercise-like metabolic status, the
development of PPARd modulators is of interest in treating
metabolic syndrome. In fact, a high aﬃnity synthetic agonist,
GW501516, has been shown to reduce weight gain and de-
crease circulating TG in high fat fed or ob/ob mice [18,24].
This eﬀect is believed to be mediated by increased peripheral
fatty acid catabolism. In obese rhesus monkeys, this agonist
at doses up to 3 mg/kg body weight/day ameliorated dyslipide-
mia, lowering TG and LDL-c and increasing HDL-c, while
weight gain was not aﬀected [8]. The most impressive eﬀect
in this study appeared to be the 79% increase in HDL-c, which
correlated with an increase in HDL particles and in levels of
apolipoproteins, including apoA-I, apoA-II and apoC-III.
The HDL-c raising activity was attributed to the induction
of a cholesterol eﬄux pump ABCA1 by PPARd demonstrated
in monocytic cells and ﬁbroblasts. GW501516 and another
agonist L165041 also increased HDL-c in db/db mice, albeit
to a lesser extent (30–40%) [10,25]. Interestingly, in mouse
macrophages, it has been shown that both ABCA1 expression
and ABCA1 mediated cholesterol eﬄux were unaﬀected by
GW501516 treatment or PPARd gene deletion [26]. It is un-
clear whether the mechanistic discrepancy is due to species dif-
ferences or other mechanisms, such as increased apoA-I levels,
are responsible for the HDL-c raising eﬀect of PPARd ago-
nists. In addition, whether PPARd activation could reduce adi-
posity in humans remains to be determined.3.2. Insulin resistance and hepatosteatosis
The eﬀect of GW501516 on glucose homeostasis has been
studied in several mouse models of insulin resistance/type II
diabetes. In high fat fed C57BL/6 mice, co-administration of
this PPARd agonist at 3 mg/kg/day for 2 months increased
the metabolic rate, reduced fatty liver and decreased lipid accu-
mulation and increased mitochondrial biogenesis in muscle.
Circulating insulin levels also declined, whereas the improve-
ment in glucose tolerance and insulin sensitivity determined
by the glucose and insulin tolerant test (GTT and ITT) was
moderate [24]. Nevertheless, the eﬀect appeared to be dose-
dependent, as at 10 mg/kg/day, the ability of GW501516 to
lower blood glucose levels and enhance glucose tolerance be-
came apparent [18]. Interestingly, in addition to improving glu-
cose homeostasis, GW501516 treatment normalized pancreatic
islet hypertrophy and increased glucose-stimulated insulin
secretion in ob/ob mice [24]. GW501516 did not induce insulin
release in isolated islets [27], suggesting the increased insulin
secretion was secondary to the improved islet function. The
molecular mechanism underlying the enhanced glucose metab-
olism was proposed to be mediated by increased fatty acid
catabolism in muscle. In fact, gene expression analyses
revealed that levels of LCAD, UCP2/3, CPT1, PGC-1a and
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ligand treated animals.
Although these studies demonstrate a potential insulin
sensitizing activity of PPARd agonists, precaution needs to
be taken in data interpretation. Notably, long-term treatment
with GW501516 reduces weight gain in mice, which could be
responsible for most observed eﬀects [18,24]. Furthermore,
although GW501516 has a relative high aﬃnity for PPARd,
the local concentrations in certain tissues may be high enough
to activate PPARa or PPARc [8]. These concerns were par-
tially addressed in a study, in which GW501516 was given to
mice that had already developed obesity and insulin resistance,
at 2 mg/kg/day for 2 weeks [25]. In diet induced obese and db/
db mice, this regimen eﬀectively lowered blood glucose and
insulin and increased glucose tolerance before changes in
weight gain and circulating lipid parameters surfaced. This
activity was completed abolished in PPARd/ mice, demon-
strating PPARd dependency. PPARd/ mice also exhibited
other metabolic defects, including a lower metabolic rate and
respiratory exchange ratio and glucose intolerance. The insulin
sensitizing activity of GW501516 was further characterized by
the euglycemic-hyperinsulinemic clamp in db/db mice. Ligand
treatment enabled insulin to suppress free fatty acid release by
adipocytes and lowered hepatic glucose production at the basal
state and during clamp. Interestingly, while the calculated
insulin stimulated glucose disposal was enhanced by ligand,
the total glucose disposal rates were similar between
GW501516 and vehicle treated group. Given that the muscle
is the major site of glucose disposal, these results suggest that
the metabolic eﬀects in the liver mediated by PPARd activation
occur prior to notable changes in the muscle. Consistent with
this idea, DNA array analyses demonstrated that most expres-
sion diﬀerences were in the liver, where a cluster of lipogenic
genes, including fatty acid synthase (FAS) and acetyl-CoA car-
boxylase (ACC), were induced by ligand treatment. At the ﬁrst
glance, these observations seem to contradict the known
PPARd activity. It is proposed that the glucose lowering eﬀect
is mediated, in part, by metabolizing glucose for lipogenesis in
the liver. In fact, there was a moderate increase in TG levels in
livers of ligand treated mice. The newly made fats are
consumed through increased fatty acid oxidation in muscle
at a later stage, as long-term ligand administration reduces
hepatic lipid content.
The combined hepatic and muscular eﬀects of PPARd ap-
pear to constitute a ‘‘fatty acid futile cycle’’, resulting in im-
proved glucose and lipid metabolism. However, the lipogenic
activity in the liver can be a concern as hepatosteatosis is com-
mon in diabetic patients. The eﬀect of GW501516 on steatosis
has been examined in a mouse model of non-alcoholic steao-
hepatitis (NASH) induced by a diet deﬁcient in methionine
and choline [28]. This diet induced massive lipid accumulation
and inﬂammatory cell inﬁltration in the liver. Co-administra-
tion of GW501516 at 10 mg/kg/day for 5 weeks reduced hepa-
tic TG and numbers of fatty droplets and inﬂammatory cells.
Furthermore, the expression of pro-inﬂammatory markers,
such as monocyte chemoattractant protein-1 (MCP-1), tumor
necrosis factor a (TNFa), interleukin-1b (IL-1b) and IL-6
was down-regulated by ligand treatment, consistent with the
ability of PPARd agonists to suppress inﬂammation in macro-
phages (see below). Collectively, these ﬁndings suggest that
PPARd is a potential therapeutic target for insulin resistance
and hepatic steatosis.3.3. Atherosclerosis
Macrophage derived foam cells are a major component of
atherosclerotic lesions [29,30]. The formation of foam cells is
facilitated by elevated LDL-c and inﬂammatory response with-
in the vessel wall. Studies in cultured mouse macrophages have
demonstrated that PPARd activation by GW501516 did not
aﬀect cholesterol accumulation or eﬄux, while it suppressed
levels of inﬂammatory mediators, such as MCP-1, MCP-3
and IL-1b [26], suggesting PPARd could be atheroprotective.
However, LDL receptor (LDLR)/ mice reconstituted with
PPARd/ bone marrow developed less lesions than those
with wild type bone marrow [26]. This unexpected result was
attributed to a receptor activation-like phenotype in
PPARd/ macrophages, due to a unique property of unli-
ganded PPARd to interact with repressors and co-repressors
in the macrophage. The suppression of inﬂammatory genes
(trans-repression), such as MCP-1, by PPARd activation is
mediated partly by ligand induced release of a transcriptional
repressor, BCL-6, which then binds to and suppresses the
promoters of several cytokines and chemokines. PPARd/
results in BCL-6 availability similar to that of ligand activa-
tion. On the other hand, for direct transcriptional targets such
as ADRP, unliganded PPARd actively represses transcription
and PPARd/ relieves the repression leading to increased
basal expression, again, similar to that of ligand activation
[31].
The loss-of-function study was confounded by the repressor
sequestering activity of unliganded PPARd. Receptor activa-
tion, however, is expected to inhibit lesion progression, since
PPARd agonists exhibit HDL-c raising and anti-inﬂammatory
activities. The eﬀect of a less characterized PPARd agonist,
GW0742, on atherogenesis has been examined in LDLR/
mice. At a high dose of 60 mg/kg/day, GW0742 treatment
for 10 weeks was able to reduce lesions in aortic valves by
55% [9], whereas it had no eﬀect at either 5 or 6 mg/kg/day
[9,32]. Although the expression of inﬂammatory markers in
aortas was down-regulated by GW0742, levels of insulin and
HDL-c were unchanged and weight gain was increased, which
were in sharp contrast to the activities of GW501516 discussed
earlier. The reason for the discrepancy in the therapeutic eﬀects
between the two agonists may be explained by diﬀerences in
their eﬃcacies. In cell-based transactivation assays, GW0742
has an EC50 of 30 nM, whereas the EC50 of GW501516 is
1 nM [8,9]. It has yet to be determined whether GW501516
can increase HDL-c in mouse models of atherosclerosis, such
as LDLR/ or apoE/ mice, and inhibit lesion progres-
sion.3.4. Inﬂammatory bowel disease and colorectal cancer
Inﬂammatory bowel disease (IBD), a collective term for
Crohns disease and ulcerative colitis, is characterized by sus-
tained activation of mucosal immune response against normal
constituents of luminal microﬂora, leading to long-term dam-
age of gastrointestinal function [33,34]. The etiology of IBD is
not completely understood. Defects in the barrier function of
intestinal epithelium and the mucosal immune system are likely
involved in the pathogenesis of this disease. PPARd is abun-
dantly expressed in the gastrointestinal tract. When
PPARd/ mice were subjected to experimental colitis in-
duced by dextran sodium sulfate (DDS), they exhibited more
severe symptoms in weight loss, shortened colon length and
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PPARd may play a role in the etiology of IBD [35]. The mech-
anism underlying the protective function of PPARd remains
elusive but is likely mediated by its ability to modulate the
function and immune response of endothelium. PPARd/
mice have been shown to have reduced numbers of Paneth
cells, which are one of the four epithelial cell types and are
responsible for the antimicrobial activity in the mouse intestine
[36]. As a result, PPARd/ mice were found to have altered
populations of the gut microﬂora. It is proposed that PPARd
is downstream of the Wnt-b-catenin/TCF4 pathway in regulat-
ing the proliferation and diﬀerentiation of Paneth cells from
stem cells. These ﬁndings suggest that PPARd may regulate
microﬂora homeostasis and intestinal epithelium integrity
thereby alleviating the symptoms of experimental colitis.
The potential beneﬁcial eﬀect of PPARd in epithelial cell re-
newal in IBD could turn out to be a double-edged sword, as
uncontrolled Wnt-b-catenin/TCF4 signaling through muta-
tions in the adenomatous polyposis coli (APC) tumor suppres-
sor gene causes colorectal cancer [37]. The role of PPARd in
colorectal carcinogenesis has been under heated debate. It
has been hypothesized that the Wnt-b-catenin/TCF4 pathway
activates the expression of PPARd to stimulate cell prolifera-
tion [38]. Supporting this hypothesis were the ﬁndings that
GW501516 treatment increased while deletion of PPARd de-
creased adenoma growth in APCmin mice [16,39]. PPARd acti-
vation was shown to promote epithelial cell survival through
the Akt signaling pathway. A similar anti-apoptotic property
of PPARd has been reported in keratinocytes during wound
healing [15]. In sharp contrast, two other studies demonstrated
that deletion of PPARd increased intestinal polyp formation in
APCmin mice [40,41]. Furthermore, The expression of PPARd
was suppressed, rather than enhanced by APC inactivation.
The apparent diﬀerence between these studies was the use of
two diﬀerent PPARd knockout lines, both of which, however,
have been shown to have no detectable PPARd protein [13,14].
Undoubtedly, more studies, including the use of intestine spe-
ciﬁc knockout mice, are needed before any conclusion regard-
ing the role of PPARd in tumorigenesis can be reached.4. Conclusions
Adipocyte hypertrophy and dysfunction in obesity results in
ectopic fatty acid accumulation leading to lipotoxicity in
tissues such as pancreas (b cells), muscle and heart, which is
believed to be one of the major causes of metabolic diseases
[42,43]. Work from animal models suggests that PPARd acti-
vation reduces fat burden exerting many favorable activities,
including reducing weight gain, increasing skeletal muscle met-
abolic rate and endurance, improving insulin sensitivity and
cardiovascular function and suppressing atherogenic inﬂam-
mation. Therefore, the development of PPARd agonists/mod-
ulators may be useful for treating the whole spectrum of
metabolic syndrome. Nevertheless, the relevance of these ﬁnd-
ings to human pathophysiology remains to be determined.
Recent epidemiology studies show evidence suggesting that
PPARd polymorphisms are associated with body mass index,
fasting glucose levels and insulin resistance [44,45]. The result
of the ﬁrst human trial with PPARd agonist has been reported
[46]. In this study with a small cohort, healthy volunteers were
given placebo or GW501516 at 2.5 mg or 10 mg once daily for2 weeks while hospitalized and sedentary. No toxicity was ob-
served during this treatment period. Both regimens reduced
circulating TG and prevented the decline of HDL-c and
apoA-I levels due to lack of physical activity. There was no
information regarding weight gain. These studies, although
limited, provide certain validation for results from animal
work. A critical question to be addressed is whether PPARd
is tumorigenic, even though the carcinogenic activity of other
PPAR agonists appear to be speciﬁc to rodents. Lastly, meta-
bolic dysregulation is now recognized as a state of low grade,
chronic inﬂammation [23]. Consistent with this idea, free fatty
acids have been shown to induce inﬂammatory response
through toll-like receptor 4 [47]. Furthermore, analogous to
the macrophage/endothelium interaction at the vascular wall,
the crosstalk between adipocytes and adipose resident macro-
phages is proposed to play an important role in metabolic dys-
regulation and insulin resistance [48,49]. Future studies
designed to dissect the function of PPARd in these processes
will undoubtedly identify novel therapeutic pathways to con-
trol the progression of metabolic diseases.
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